Physician profile
Ali T Dural
NPI 1376543470
$2,613.29
in general payments reported to CMS, 2019-2025
14 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $246 · 2022: $460 · 2023: $271 · 2024: $680 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.81 | 2019-2025 | Skyrizi, Rinvoq |
| Ipsen Biopharmaceuticals, INC | $277.77 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $165.84 | 2024 | Entyvio |
| Janssen Biotech, INC. | $147.27 | 2024 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $125.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $124.72 | 2023 | Zeposia |
| Qol Medical, LLC | $121.85 | 2024 | Sucraid |
| Redhill Biopharma INC. | $103.88 | 2020 | |
| Ardelyx, INC. | $86.38 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $20.27 | 2025 | Vowst |
| Romark Laboratories, Lc | $16.44 | 2019 | |
| Celgene Corporation | $16.07 | 2023 | Zeposia |
| Conmed Corporation | $13.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Dural listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.